{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Tonix+Pharmaceuticals%2C+Inc.", "query": { "sponsor": "Tonix Pharmaceuticals, Inc.", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Tonix+Pharmaceuticals%2C+Inc.&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Tonix+Pharmaceuticals%2C+Inc.&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T03:01:27.392Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02277704", "title": "Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 245, "start_date": "2014-10", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 23, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Imperial", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277704" }, { "nct_id": "NCT05679908", "title": "A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Migraine", "Chronic Migraine, Headache", "Chronic Migraine Without Aura", "Aura Migraine" ], "interventions": [ { "name": "TNX-1900", "type": "DRUG" }, { "name": "Placebo Nasal Spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 88, "start_date": "2022-12-06", "completion_date": "2023-10-23", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 26, "location_summary": "Little Rock, Arkansas • Lemon Grove, California • Oceanside, California + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05679908" }, { "nct_id": "NCT03110575", "title": "12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 190, "start_date": "2017-06-20", "completion_date": "2018-07-27", "has_results": true, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Rogers, Arkansas • Beverly Hills, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110575" }, { "nct_id": "NCT02436096", "title": "A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibromyalgia", "Myofascial Pain Syndromes", "Muscular Diseases", "Musculoskeletal Diseases", "Nervous System Diseases", "Neuromuscular Diseases", "Rheumatic Diseases" ], "interventions": [ { "name": "TNX-102 SL Tablet, 2.8mg", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 519, "start_date": "2015-04", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Brandon", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02436096" }, { "nct_id": "NCT02829814", "title": "Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibromyalgia", "Myofascial Pain Syndromes", "Muscular Diseases", "Nervous System Diseases", "Neuromuscular Diseases", "Rheumatic Diseases", "Musculoskeletal Diseases" ], "interventions": [ { "name": "TNX-102 SL Tablet, 2.8 mg", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 51, "start_date": "2016-07-22", "completion_date": "2016-09-13", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Brandon", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02829814" }, { "nct_id": "NCT04508621", "title": "A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibromyalgia" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 514, "start_date": "2020-07-22", "completion_date": "2021-11-01", "has_results": true, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508621" }, { "nct_id": "NCT07464535", "title": "A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects (HS)" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2022-03-18", "completion_date": "2022-04-30", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07464535" }, { "nct_id": "NCT05472090", "title": "A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection", "COVID-19", "Long COVID", "Long Haul COVID" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 63, "start_date": "2022-08-18", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oceanside", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05472090" }, { "nct_id": "NCT02421679", "title": "Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 159, "start_date": "2015-04-14", "completion_date": "2016-05-26", "has_results": true, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 22, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 19 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Imperial", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02421679" }, { "nct_id": "NCT04996056", "title": "An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine Intoxication" ], "interventions": [ { "name": "TNX-1300", "type": "DRUG" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 0, "start_date": "2021-09-03", "completion_date": "2022-06-16", "has_results": false, "last_update_posted_date": "2022-06-29", "last_synced_at": "2026-10-11T03:01:27.392Z", "location_count": 2, "location_summary": "Detroit, Michigan • St Louis, Missouri", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04996056" } ] }